795.57 USD
-27.37 (-3.33%)
795.57 USD
0 (0%)
Taking everything into account, ARGX scores 6 out of 10 in our fundamental rating. ARGX was compared to 530 industry peers in the Biotechnology industry. While ARGX has a great health rating, its profitability is only average at the moment. ARGX is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes ARGX very considerable for growth investing!
1. Profitability
1.1 Basic Checks
ARGX had positive earnings in the past year.
ARGX had a positive operating cash flow in the past year.
ARGX had negative earnings in 4 of the past 5 years.
ARGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 17.84%, ARGX belongs to the best of the industry, outperforming 96.42% of the companies in the same industry.
ARGX has a better Return On Equity (21.00%) than 96.23% of its industry peers.
ARGX's Return On Invested Capital of 6.01% is amongst the best of the industry. ARGX outperforms 92.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 6.01% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 41.97%, ARGX belongs to the best of the industry, outperforming 97.36% of the companies in the same industry.
With an excellent Operating Margin value of 15.30%, ARGX belongs to the best of the industry, outperforming 93.21% of the companies in the same industry.
The Gross Margin of ARGX (89.40%) is better than 91.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ARGX is destroying value.
The number of shares outstanding for ARGX has been increased compared to 1 year ago.
Compared to 5 years ago, ARGX has more shares outstanding
Compared to 1 year ago, ARGX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 28.64 indicates that ARGX is not in any danger for bankruptcy at the moment.
ARGX has a better Altman-Z score (28.64) than 93.02% of its industry peers.
ARGX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
ARGX has a Debt to FCF ratio of 0.14. This is amongst the best in the industry. ARGX outperforms 95.66% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
The Debt to Equity ratio of ARGX (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 28.64 |
ROIC/WACC0.81
WACC7.43%
2.3 Liquidity
ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a Current ratio (5.60) which is in line with its industry peers.
A Quick Ratio of 5.27 indicates that ARGX has no problem at all paying its short term obligations.
With a Quick ratio value of 5.27, ARGX perfoms like the industry average, outperforming 59.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1512.50%, which is quite impressive.
ARGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.71%.
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
3.2 Future
Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 107.34% on average per year.
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 34.98% on average per year.
EPS Next Y935.48%
EPS Next 2Y313.05%
EPS Next 3Y178.04%
EPS Next 5Y107.34%
Revenue Next Year95.19%
Revenue Next 2Y63.47%
Revenue Next 3Y48.27%
Revenue Next 5Y34.98%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ARGX is valuated quite expensively with a Price/Earnings ratio of 59.33.
90.75% of the companies in the same industry are more expensive than ARGX, based on the Price/Earnings ratio.
ARGX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.00.
With a Price/Forward Earnings ratio of 24.98, ARGX is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ARGX is valued cheaper than 92.83% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ARGX to the average of the S&P500 Index (23.70), we can say ARGX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.33 | ||
| Fwd PE | 24.98 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ARGX is valued cheaper than 89.81% of the companies in the same industry.
ARGX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ARGX is cheaper than 91.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 158.66 | ||
| EV/EBITDA | 88.49 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARGX's earnings are expected to grow with 178.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y313.05%
EPS Next 3Y178.04%
5. Dividend
5.1 Amount
No dividends for ARGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
795.57
-27.37 (-3.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners43.42%
Inst Owner Change0%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap48.98B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts83.2
Price Target972.7 (22.26%)
Short Float %3.05%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14.45%
Revenue beat(16)13
Avg Revenue beat(16)17.87%
PT rev (1m)0.99%
PT rev (3m)13.99%
EPS NQ rev (1m)0.26%
EPS NQ rev (3m)0.72%
EPS NY rev (1m)-0.42%
EPS NY rev (3m)15.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.56%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)5.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.33 | ||
| Fwd PE | 24.98 | ||
| P/S | 16.05 | ||
| P/FCF | 158.66 | ||
| P/OCF | 121.32 | ||
| P/B | 8.04 | ||
| P/tB | 8.33 | ||
| EV/EBITDA | 88.49 |
EPS(TTM)13.41
EY1.69%
EPS(NY)31.85
Fwd EY4%
FCF(TTM)5.01
FCFY0.63%
OCF(TTM)6.56
OCFY0.82%
SpS49.55
BVpS99.01
TBVpS95.45
PEG (NY)0.06
PEG (5Y)N/A
Graham Number172.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 6.01% | ||
| ROICexc | 16.72% | ||
| ROICexgc | 18.56% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 28.64 |
F-Score6
WACC7.43%
ROIC/WACC0.81
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y935.48%
EPS Next 2Y313.05%
EPS Next 3Y178.04%
EPS Next 5Y107.34%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
Revenue Next Year95.19%
Revenue Next 2Y63.47%
Revenue Next 3Y48.27%
Revenue Next 5Y34.98%
EBIT growth 1Y208.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1529.77%
EBIT Next 3Y219.36%
EBIT Next 5Y122.64%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.76%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE - ADR / ARGX FAQ
What is the fundamental rating for ARGX stock?
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.
What is the valuation status for ARGX stock?
ChartMill assigns a valuation rating of 6 / 10 to ARGENX SE - ADR (ARGX). This can be considered as Fairly Valued.
Can you provide the profitability details for ARGENX SE - ADR?
ARGENX SE - ADR (ARGX) has a profitability rating of 5 / 10.
What are the PE and PB ratios of ARGENX SE - ADR (ARGX) stock?
The Price/Earnings (PE) ratio for ARGENX SE - ADR (ARGX) is 59.33 and the Price/Book (PB) ratio is 8.04.
What is the earnings growth outlook for ARGENX SE - ADR?
The Earnings per Share (EPS) of ARGENX SE - ADR (ARGX) is expected to grow by 935.48% in the next year.